It is therefore possible that the N-terminal GAD65-restricted GADA, as proposed, does not detect individuals with autoimmune type 1 diabetes, at least using clinical phenotype as a proxy, whilst screening for t-GADA could be helpful for clinical assessment and prediction of insulin therapy. This evidence concerns the gene INS and autoimmune type 1 diabetes.